Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer

Autoři: Lucas Maahs aff001;  Bertha E. Sanchez aff001;  Nilesh Gupta aff002;  Meredith Van Harn aff003;  Evelyn R. Barrack aff004;  Prem-veer Reddy aff004;  Clara Hwang aff005
Působiště autorů: Department of Internal Medicine, Henry Ford Health System, Detroit, MI, United States of America aff001;  Department of Pathology, Henry Ford Health System, Detroit, MI, United States of America aff002;  Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, United States of America aff003;  Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, United States of America aff004;  Division of Hematology/Oncology, Henry Ford Health System, Detroit, MI, United States of America aff005
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article


About half of the patients treated with docetaxel in the setting of metastatic castration-resistant prostate cancer (CRPC) are non-responders. Therefore, a marker of response would be beneficial for clinical decision-making. We evaluated class III β-tubulin (βIII-tubulin) expression as a predictor of resistance in this setting, which previously has been correlated with lack of response to taxanes in other cancers. Patients with CRPC were included if they were treated with at least 3 cycles of docetaxel between 1990 and 2011. βIII-tubulin expression was assessed by immunostaining, which was performed in tissue samples obtained either via biopsy or prostatectomy at the time of diagnosis. Rates of prostate-specific antigen (PSA) response and overall survival (OS) following docetaxel treatment were compared between patients with high (2+ or 3+ staining) vs. low (0 or 1+ staining) βIII-tubulin expression. Of 73 patients, 26 (35%) had a high expression of βIII-tubulin. A PSA decline of 10% or greater occurred in 65% of patients with a high βIII-tubulin expression vs. 89% with a low βIII-tubulin expression (p = 0.0267). The median OS for patients with a high βIII-tubulin expression was 17.4 (95% CI 8.7–21.0) months vs. 19.8 (95% CI 16.6–23.6) months for patients with a low expression (p = 0.039). Our results show that a high βIII-tubulin expression is a negative prognostic factor in metastatic CRPC patients treated with docetaxel.

Klíčová slova:

Biopsy – Cancer detection and diagnosis – Cancer treatment – Cell staining – Immunostaining – Metastasis – Oncology – Prostate cancer


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68: 7–30. doi: 10.3322/caac.21442 29313949

2. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single-Institution Experience With Radical Prostatectomy and External-Beam Radiotherapy. J Clin Oncol. 2002;20(16): 3376–3385. doi: 10.1200/JCO.2002.01.150 12177097

3. Bianco FJ, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual function and urinary function (“trifecta”). Urology. 2005;66(5): 83–94.

4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2): 517–23. doi: 10.1097/01.ju.0000045749.90353.c7 12544300

5. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8): 737–746. doi: 10.1056/NEJMoa1503747 26244877

6. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2018. doi: 10.1016/j.eururo.2018.03.028 29673712

7. Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol. 2012;4(6): 329–340. doi: 10.1177/1758834012449685 23118808

8. Magadoux L, Isambert N, Plenchette S, Jeannin J, Laurens V. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (Review). Int J Oncol. 2014;45(3): 919–928. doi: 10.3892/ijo.2014.2517 24969394

9. Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, et al. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol. 2013;18(3): 371–379. doi: 10.1007/s10147-012-0386-8 22358390

10. Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, et al. Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol. 2006;28(2): 375–381. 16391792

11. Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L, et al. Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Cancer Res. 2010;70(22): 9253–9264. doi: 10.1158/0008-5472.CAN-10-1447 21045157

12. Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissière-Michot F, Maillé P, et al. Increased expression of class III β-tubulin in castration-resistant human prostate cancer. Br J Cancer. 2009;101(6): 951–956. doi: 10.1038/sj.bjc.6605245 19690549

13. Shimada K, Ishikawa T, Kita K, Narui K, Sugae S, Shimizu D, et al. Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype. Anticancer Res. 2015;35(2): 907–912. 25667473

14. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, et al. Prediction of Response to Docetaxel by Quantitative Analysis of Class I and III β-Tubulin Isotype mRNA Expression in Human Breast Cancers. Clin Cancer Res. 2003;9: 2992–2997. 12912947

15. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J. 2005;19(10): 1299–1301. doi: 10.1096/fj.04-3178fje 15946994

16. Mhaidat NM, Thorne RF, de Bock CE, Zhang XD, Hersey P. Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III β-tubulin levels. FEBS Lett. 2008;582(2): 267–272. doi: 10.1016/j.febslet.2007.12.014 18086570

17. Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, et al. Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009;20(8): 1414–1419. doi: 10.1093/annonc/mdp002 19468031

18. Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, et al. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol. 2013;209(1): 62.e1–62.e9.

19. Du J, Li B, Fang Y, Liu Y, Wang Y, Li J, et al. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer. 2015. doi: 10.1186/s12885-015-1553-x 26198101

20. Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, et al. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis. 2014;31(1): 101–110. doi: 10.1007/s10585-013-9614-5 24005572

21. Hwang JE, Hong JY, Kim K, Kim SH, Choi WY, Kim MJ, et al. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent or metastatic gastric cancer. BMC Cancer. 2013. doi: 10.1186/1471-2407-13-431 24053422

22. Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T, et al. Class III β-Tubulin Expression in Tumor Cells is Correlated with Resistance to Docetaxel in Patients with Completely Resected Non-Small-Cell Lung Cancer. Intern Med. 2009;48(4): 203–208. doi: 10.2169/internalmedicine.48.1659 19218769

23. Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, et al. Class III β-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology. 2007;51(4): 539–546. doi: 10.1111/j.1365-2559.2007.02792.x 17714470

24. Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol. 2008;9(2): 168–175. doi: 10.1016/S1470-2045(08)70029-9 18237851

25. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003;56(1): 45–56. doi: 10.1002/cm.10132 12905530

26. Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, et al. Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clin Cancer Res. 2008;14(14): 4511–4516. doi: 10.1158/1078-0432.CCR-07-4741 18628466

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden